Steven Cohen Gh Research PLC Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.02 - $10.92 $148,092 - $268,632	-24,600 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$9.2 - $13.5 $1.64 Million - $2.4 Million	-178,000 Reduced 87.86%	24,600 $239,000
Q3 2022 Nov 14, 2022	SELL	$10.15 - $16.15 $291,305 - $463,504	-28,700 Reduced 12.41%	202,600 $2.35 Million
Q2 2022 Aug 15, 2022	SELL	$8.99 - $19.87 $370,388 - $818,644	-41,200 Reduced 15.12%	231,300 $2.31 Million
Q1 2022 May 16, 2022	SELL	$15.48 - $23.98 $595,980 - $923,230	-38,500 Reduced 12.38%	272,500 $4.98 Million
Q4 2021 Feb 14, 2022	BUY	$14.1 - $27.9 $4.39 Million - $8.68 Million	311,000 New	311,000 $7.26 Million

23.5M

63.1K

1.9K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $433M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.